Overview: Vaccine hopes lift 2021 prospects ▀ The recent vaccine news points to a faster vaccination rollout than we had previously assumed. As a result, we have raised our world GDP growth forecast for 2021 to 5.2% from 4.9%, after an estimated 4.0% decline in 2020, and now judge the risks around our baseline forecast to be more broadly balanced. ▀ The global economy is set to end 2020 on a weak note as a result of many economies, particularly in Europe, re‐imposing activity restrictions to contain the pandemic. Nonetheless, the survey data point to a relatively mild downturn at a global level. Despite the eurozone and UK composite PMIs falling back into recession territory in November, the global composite PMI barely fell, reflecting improvements in the US and elsewhere. ▀ More importantly, but conditional on the Pfizer/BioNTech, Oxford/AstraZeneca and Moderna vaccines quickly gaining approval for use, it seems increasingly likely that some advanced economies (AEs) could vaccinate significant proportions of their most vulnerable cohorts early next year. Reflecting this, we now expect many AEs to begin a meaningful and sustained lifting of restrictions around March/April time, triggering a mid‐year mini‐boom in these economies. ▀ Most emerging markets (EMs) are likely to see slower vaccine rollout, suggesting that the near‐term lift for these economies will be smaller. Nonetheless, stronger demand from AEs, rising commodity prices and the ongoing weakening of the US dollar should all be supportive for the outlook. ▀ The light at the end of the tunnel will allow governments to reverse some of the exceptional policy support measures put in place this year and allow the passing of the growth baton from the public to the private sector. While this is a necessary part of the recovery process, it will be a difficult transition and there are likely to be bumps in the process. So, although the chances of a stronger recovery have risen, we still see medium‐term economic scarring from the pandemic.
Read full abstract